Total number of projects: 5
As coordinator: 1
As participant: 4
Sole participant: 0
Coordinator / Participant Ratio: 0.25*
Total project funding [€]: | Projects [No]: | |||||
---|---|---|---|---|---|---|
Year: | coordinator* | participant* | per partner | as coordinator | as participant | |
2014 | 0 | 5.999.995 | 223.020 | 1 | ||
2013 | 29.998.903 | 14.996.100 | 12.807.944 | 1 | 3 |
Total number of partners: 442
Partner loyalty:
Frequent Partner: (> 2 projects): 66
Rare Partner: 376
Frequent / Rare Partner Ratio: 0.18
Start date | Project | acronym | role | funding | partners |
---|---|---|---|---|---|
2014-02-01 | Diagnostic Imaging Strategies for Patients with Stable Chest Pain and Intermediate Risk of Coronary Artery Disease: Comparative Effectiveness Research of Existing Technologies | DISCHARGE | participant | 5.999.995 | 28 |
2013-12-01 | A Phase Ib/II study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor PF-02341066 in KRASMT and KRASWT (with aberrant c-MET) Colorectal Cancer Patients | MERCURIC | participant | 5.999.995 | 13 |
2013-10-01 | Collaborative European NeuroTrauma Effectiveness Research in TBI | CENTER-TBI | coordinator | 29.998.903 | 38 |
2013-10-01 | Optimizing Exercise Training in Prevention and Treatment of Diastolic Heart Failure | OPTIMEX | participant | 2.999.995 | 6 |
2013-09-01 | Cancer Vaccine development for Hepatocellular Carcinoma | HEPAVAC | participant | 5.996.111 | 9 |